Peptide Briefs

Questions about peptides? We've got you.
• What the studies actually show
• Evidence graded A–D
• Human data vs. animal data, sorted
Ed.D. | 2 yrs in China | Ki

[Peptide Briefs @PeptideBriefs]

Well, you know how every time you look up a peptide, one page says it works & the next says it doesn't?

Most people trying to learn hit that wall.

We're two teachers, so we built a library with a rubric: every compound graded A to D, with the work shown. https://t.co/LMfauruOmr

[Peptide Briefs @PeptideBriefs]

The link to library is in the guide and here: https://t.co/rScqnzDp6q

[Peptide Briefs @PeptideBriefs]

Well, you know how every time you look up a peptide, one page says it works & the next says it doesn't?

Most people trying to learn hit that wall.

We're two teachers, so we built a library with a rubric: every compound graded A to D, with the work shown. https://t.co/LMfauruOmr

[Peptide Briefs @PeptideBriefs]

Used needles never go loose in the household trash, the recycling bin, or down the toilet.

They go in a puncture-proof sharps container: a purpose-made one, or a heavy plastic bottle with a tight lid, like an empty laundry detergent jug.

Disposal rules differ by state. Look yours up, with drop-off sites, at https://t.co/gqJTuNx3FE

[Peptide Briefs @PeptideBriefs]

🔬 Myth: a manufacturer's COA is enough on its own.
Fact: that's grading your own homework. Independent verification is the standard.

For research use only.

#AgapeCompounds #ScienceSaturday #COA

[Peptide Briefs @PeptideBriefs]

A peptide COA proves less than most buyers think. 5 checks:

1. Lot matches the vial?
2. Who tested, and who paid?
3. Method named for every result?
4. Verifiable at the lab?
5. Site claims match the certificate?

Walkthrough:

https://t.co/aeJiSJrMea

[Peptide Briefs @PeptideBriefs]

@researchitgg Agreed. And a step before clinical endpoints is missing too: as far as we can find, no placebo-controlled study has measured telomere length in people before and after. The evidence chain currently stops at the cell culture dish.

[Peptide Briefs @PeptideBriefs]

Epitalon is sold as the telomere peptide. In July an FDA advisory panel voted 7 to 4 to recommend letting pharmacies compound it. Peptide Briefs grades it a C. Here is what the published evidence shows, and what it doesn't.

[Peptide Briefs @PeptideBriefs]

@EricTopol @ScienceMagazine A live example: in July the FDA's compounding advisory panel recommended six peptides, including epitalon, against the advice of the agency's own staff. Epitalon has no published controlled human trials. Validated endpoints would have made that an easier call.

[Peptide Briefs @PeptideBriefs]

@NEJM @EASDnews Two things stand out in this figure. 35% of the placebo group also lost 5% or more, which is why the higher thresholds are the ones to watch. And at the 20% threshold the two doses nearly converge: 10.4% vs 11.2%. The higher dose adds little at the top end.

[Peptide Briefs @PeptideBriefs]

@DrJesseMorse Worth noting the figure gives two numbers per arm: on-treatment and all-randomized. 9 mg is 25.9% vs 25.0%. The gap is small here, which says something good about tolerability. But the second number is the one to quote.

[Peptide Briefs @PeptideBriefs]

@OSHOMAH01 The 70% is the share of people who responded, not the size of the increase: 7 of 10 on the copper peptide cream, 5 of 10 on vitamin C, 4 of 10 on tretinoin. Abdulghani 1998, topical, thigh skin, biopsy-measured.

[Peptide Briefs @PeptideBriefs]

@MWeintraubMD Worth noting the scale: REMODEL was 106 participants, 52 weeks, biopsies in 33. "Prevented fibrosis" is inferred from a stable MRI marker. It explains how the benefit might happen. FLOW is what showed that it does.

[Peptide Briefs @PeptideBriefs]

Helpful table. The citation column deserves as close a read as the effect column. The rows range from published trial analyses (Deanfield, Colhoun) to a preprint, two conference presentations, and a mouse model with a pilot trial. Same table, quite different levels of evidence per row.

[Peptide Briefs @PeptideBriefs]

Useful chart. One thing that stands out: the two glucagon-containing drugs sit at opposite ends. Retatrutide at the top, survodutide at the bottom. Hard to credit glucagon alone for the gap. Trial length and baseline BMI would be good columns to add, since placebo-adjusting doesn't correct for either.

[Peptide Briefs @PeptideBriefs]

Which trial is the 3% from? Worth pinning down, since the Phase 3 readouts differ by population and dose.
Also worth noting that lost any weight is a low bar. The comparison that matters is against placebo, and at thresholds like 5% or more. Plenty of placebo participants lose some weight too.

[Peptide Briefs @PeptideBriefs]

Worth adding the design details: TriNetX records, about 81,000 GLP-1 users matched to people who got diet or exercise counseling, median follow-up 2 years, HR 0.59. Two years is short for a 41% drop in cancers that take much longer to develop. That gap is why the authors ask for prospective confirmation.

[Peptide Briefs @PeptideBriefs]

Two kisspeptin posts in my feed today, both citing the same 2011 study. What it showed: IV kisspeptin-10 raised LH and testosterone in healthy men. What it didn't: anything beyond 22.5 hours, or in more than a handful of men. Strong signal. Short runway.

[Peptide Briefs @PeptideBriefs]

The 44% checks out: testosterone went from 16.6 to 24.0 nmol/L. The context matters though. That was 4 healthy men on a continuous IV infusion for 22.5 hours in a research unit. Same paper: the highest bolus produced a smaller LH response than the middle one. George et al., JCEM 2011.

[Peptide Briefs @PeptideBriefs]

Why a C: telomerase findings rest on cell culture, with one independent replication. No effect on mean lifespan in mice. Human data is on the extract, not the peptide. A good hypothesis. Not yet a result. Full page with references: https://t.co/SSNoYNHrng

[Peptide Briefs @PeptideBriefs]

Regulatory status: not FDA approved for anything. The July 24 panel vote is a recommendation, not a decision. FDA's own staff advised against it, and the agency has the final say.